Quantitative Comparison of GM1 Gangliosidosis Afflicted Ovine Tissue using Thin‐Layer Chromatography, Mass Spectrometry and Nuclear Magnetic Resonance

Abstract

GM1 ganglioside is a naturally occurring glycosphingolipid that cannot be synthesized in significant quantities; so it needs to be isolated as a natural product. Researchers at Glycoscience Research, Inc. (GRI – Toronto, SD) have developed a novel, verified, ovine source for producing GM1 ganglioside at levels needed for pharmaceutical applications. GM1 gangliosides have been shown to be an effective therapeutic against Huntington's disease as well as a potential promising lead against Parkinson's disease, Alzheimer's, and dementia (Holler, et al., 2016). Research presented here attempts to address the biochemical quantification of purified GM1 ganglioside isolated from afflicted/non‐afflicted lamb muscle to definitively show no significant differences in GM1 levels between the two meat sources. Chloroform:methanol extraction, anion exchange chromatography (AEC) and High Performance Thin‐Layer Chromatography (HPTLC) followed by Nuclear Magnetic Resonance (NMR) and MS/MS Spectrophotometry analysis compares similarities and differences in GM1 concentration levels between muscle tissue from lambs afflicted with the genetic disease of overproducing GM1 ganglioside and normal, wildtype lamb muscle.Support or Funding InformationThis material is based upon work supported by the National Science Foundation/EPSCoR Cooperative Agreement #IIA‐1355423 and by the State of South Dakota, SD‐GOED, NSF I‐Corps Team Program and Dr. Larry and Sue Holler, GlycoScience Research IncorporatedThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.